<scp>TOOKAD</scp> ^® <scp>S</scp> oluble vascular‐targeted photodynamic ( <scp>VTP</scp> ) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer

Abstract

Biopsy data, post-treatment dynamic contrast-enhancement MRI at 1 week after VTP and analysis of the safety data have shown that 4 mg/kg TOOKAD(®) Soluble and 200 J/cm light are the optimal treatment conditions for the VTP procedure resulting in >80% of patients treated with this regimen having a negative biopsy at 6 months. Overall, the treatment was well tolerated and exhibited early signs of efficacy for minimally invasive focal treatment of localised prostate cancer.